Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy



Status and phase

Phase 3


Actinic Keratosis


Drug: BF-200 ALA
Drug: Vehicle
Drug: MAL Cream

Study type


Funder types




Details and patient eligibility


The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.

Full description

This was a randomized, observer-blind, multinational, comparator and placebo-controlled parallel group, (3:3:1 ratio) study to compare the efficacy and safety of BF-200 ALA with the comparator Metvix® (methyl-[5-amino-4-oxopentanoate]) and placebo, for the treatment of AK with PDT.


571 patients




18 to 85 years old


No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria: Written informed consent. Men and women between 18 and 85 years of age. 4-8 AK lesions of 0.5 to 1.5 cm diameter of mild to moderate intensity (Olsen grade 1 and 2) in the face and/or on the bald scalp. Lesions on the eyes, nostrils, ears and mouth were not considered for treatment during the planned study. Target AK lesions were to be discrete and quantifiable; adjacent AK lesions were to show a minimum distance of 1.0 cm from one another. Confirmation of AK by biopsy taken at screening. Free of significant physical abnormalities (e.g., tattoos, dermatoses) in the potential treatment region that could have caused difficulty with examination or final evaluation. Willingness to stop the use of moisturizers and any other topical treatments within the treatment region. Good general health condition. Healthy subjects and subjects with clinically stable medical conditions including, but not limited to the following diseases (controlled hypertension, diabetes mellitus type II, hypercholesterolemia, osteoarthritis) were permitted to be included in the study if the medication taken for the treatment of the disease did not match an exclusion criterion or was not specified as prohibited concomitant medication. No extensive sunbathing or solarium use during the trial. Negative pregnancy test at screening. Main exclusion criteria: Known hypersensitivity to BF-200 ALA, MAL (methyl-aminolevulinic acid) and/or any of the ingredients of the formulations Clinically significant medical conditions (tumor disease etc.) making implementation of the protocol or interpretation of the study results difficult Presence of photodermatoses Presence of other tumors in the treatment areas within the last 4 weeks Start of treatment with phototoxic or photoallergic drugs within 8 weeks prior to screening Current treatment with immunosuppression therapy Hypersensitivity to porphyrins Presence of porphyria Presence of inherited or acquired coagulation defect Any topical treatment within the treatment area within 12 weeks before PDT1 (first PDT Treatment) Topical treatment with ALA or MAL outside the treatment area during participation in the study None of the specified systemic treatments within the designated period before PDT1

Trial design

Primary purpose




Interventional model

Parallel Assignment


Single Blind

571 participants in 3 patient groups, including a placebo group

BF-200 ALA
Active Comparator group
Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
Drug: BF-200 ALA
MAL Cream
Active Comparator group
Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
Drug: MAL Cream
Placebo Comparator group
Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
Drug: Vehicle

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems